Arbutus Biopharma Corporation (ABUS) is currently Overvalued by 244.24%

Arbutus Biopharma Corporation (ABUS) appears overvalued by approximately 244.24% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Downside (live) 244.24% (from live valuation API)
Confidence (live) 8.5/10 (High conviction overvalued)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$5.18

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Arbutus Biopharma Corporation overvalued or undervalued?

Intrinsic value work anchors Arbutus Biopharma Corporation on owner earnings and balance-sheet capacity; the current quote trades above that anchor, which frames the stock as relatively rich on a fundamentals-first view.

Versus historical valuation bands, ABUS is closer to the upper end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.

Forward market expectations are elevated: the price requires heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.

Key metrics

P/E ratio: 27.0x
Revenue growth (TTM y/y): 12%
Profit margin: 34.6%
Fair value (model): Unlock

Next steps

Frequently asked questions — ABUS

Is ABUS overvalued right now?

Based on our 2026 models, Arbutus Biopharma Corporation (ABUS) appears overvalued at $5.18 with roughly 244.2% downside versus fair value. Confirm with valuation ratios and financials before acting.

What is Arbutus Biopharma Corporation's intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether ABUS trades above or below fair value. At $5.18, Arbutus Biopharma Corporation currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Arbutus Biopharma Corporation's intrinsic value calculated?

Tickerplace calculates ABUS's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is ABUS undervalued right now?

A stock is undervalued when price sits below a supportable fair value range. Check whether ABUS's gap aligns with fundamentals using the ratios and financial links on this page.

Peers for ABUS: open their overvalued / undervalued view.

Instant valuation answer